Breast cancer treatment using a single drug is associated with a high failure rate due, in part, to the heterogeneity of drug response within individuals, nonspecific target action, drug toxicity, and/or development of resistance. Use of dual-drug therapies, including drug conjugates, may help overcome some of these roadblocks by more selective targeting of the cancer cell and by acting at multiple drug targets rather than one. Drug-conjugate approaches include linking drugs to antibodies (antibody-drug conjugates), radionuclides (radioimmunoconjugates), nanoparticles (nanoparticle-drug conjugates), or to other drugs (drug-drug conjugates). Although all of these conjugates might be designed as effective treatments against breast cancer, the focus of this review will be on drug-drug conjugates because of the increase in versatility of these types of drugs with respect to mode of action at the level of the cancer cell either by creating a novel pharmacophore or by increasing the potency and/or efficacy of the drugs' effects at their respective molecular targets. The development, synthesis, and pharmacological characteristics of drug-drug conjugates will be discussed in the context of breast cancer with the hope of enhancing drug efficacy and reducing toxicities to improve patient quality of life.
increased risk of developing breast cancer. 36 Mutation(s) of a specific signaling protein may also lead to drug resistance. For example, estrogen receptor-positive breast cancer cells (MCF-7) are known to display drug resistance by modulation of the antiapoptotic protein, Bcl2, in the presence of estrogenic stimulation. 108 Resistance may also arise through activation of drug transporters that prevent the accumulation of the anticancer drug within the cell. 46 For example, anthracycline drugs are readily effluxed from cancer cells overexpressing P-glycoprotein or multidrug resistance protein. 27 In addition, cancer phenotypes in different human populations vary, and a response to a single drug may not be equally efficacious across all individuals. 84 Drug conjugates represent a growing class of anticancer agents designed to (1) increase target selectivity and reduce the bystander effect (eg, drug-antibody conjugates; Figure 2A ; Table 1 ), (2) enhance cytotoxicity and tumor targeting (eg, radionuclide-drug conjugates, nanoparticle-drug conjugates; Figure 2B ; Tables 2 and   3 ) or (3) enhance the potency and/or efficacy of anticancer therapy (eg, drug-drug conjugates; Figure 2C ; Table 4 ). To overcome low efficacy, drug resistance, and/or toxicity associated with single drug use or monotherapy, dual-drug, and even triple-drug therapies are being developed or are already in clinical use. 1 For example, paclitaxel and trastuzumab combination drugs, or capecitabine and docetaxel combination drugs have been shown to reduce mortality and improve safety compared to their administration as single drugs. 78 However, most of these therapies deliver drug combinations as separate entities.
Drug conjugates offer an alternative approach in situations where a single drug or monotherapy fails. A drug-drug conjugate comprises 2 or more drugs connected by a chemical linker (Figure 2C and D) . These novel types of drugs may be useful for targeted drug delivery and modulation of pharmacokinetic parameters, rendering the drugs more effective and less toxic than in isolation.
Furthermore, conjugation of 2 drugs (eg, melatonin-tamoxifen) with a noncleavable linker may produce a novel molecule with unique pharmacological characteristics, 116 (US Patent No. 08785501). Although antibody-drug conjugates comprise a large segment of conjugated drugs (see Table 1 ), this class of drugs will not be discussed here, and the reader is referred to recent excellent papers. 51, 89 The focus of this review will be on the emerging field of drug-drug conjugates reported in the literature, their design and their pharmacological characteristics with respect to drug targets (receptors, intracellular signaling proteins) and efficacy as antibreast cancer agents.
| DRUG CONJUGATES/ HYBRID LIGAN DS
Ideally, a drug-drug conjugate should be stable in the systemic circulation before arriving at the target site, which is not only F I G U R E 1 Number of new drugs approved by FDA from 2011 to 2018 (data collected from https://www.fda.gov/Drugs/Development ApprovalProcess/DrugInnovation/default.htm) valid for drug conjugates with a noncleavable linker, but also for those formed by a cleavable spacer such that drug release will occur only at the intended site of action. 26 A noncleavable linker may also be designed to maintain its chemical integrity, allowing it to act as a single moiety/pharmacophore at its receptor or receptors. 72 Unlike combination drug therapy, in which 2 individual unlinked drugs are administered simultaneously, conjugated drug-drug therapies may offer distinct advantages therapeutically, aesthetically, or both. 63 With respect to esthetics, it may be more convenient for a patient to take a single drug conjugate instead of 2 drugs, thus improving compliance. 63 Concerning therapeutic advantages, conjugated drug therapies may improve the therapeutic index by lowering the minimum effective dose and by increasing the maximum tolerated dose compared to traditional combination therapies. 73 Drug-drug conjugates may also prevent drug resistance, as tumors are less likely to become resistant to drugs with distinct targets (ie, receptors, and/or intracellular signaling proteins). 1, 16 A drug conjugate may display superior activity (potency, and/or efficacy) compared to a single drug; this may be a result of improved bioavailability 119 or through additive or synergistic action of the 2 drugs working in concert. 97 Moreover, 2 conjugated pharmacophores targeted for 2 different receptors may show higher affinity by coactivation in the same cells. 48 For example, paclitaxel and doxorubicin drug conjugates showed superior efficacy and safety compared to the combination by acting synergistically because it delivers both drugs to the same target site at a synergistic ratio. 71 The increase in potency of a drugdrug conjugate may also produce less toxicity as the recommended dose could be lowered. 5, 24, 61, 62 For example, chimeric cSrc kinase and histone deacetylase inhibitors 59 and the multiacting EGFR/HER2 and histone deacetylase inhibitor CUDC-101 12 were reported to be not only more active than the combination of the 2 constituting parent compounds, but also less toxic with a higher improved therapeutic index. These findings indicate that molecular hybridization does not necessarily lead to the additive toxicity often observed for the combination therapy. Table 2 ), C = chelating agent (DOTA, EDTA) D = cytotoxic drug (mentioned in Table 1 ), E = binds with a receptor (tamoxifen, endoxifen), F = regulates a signal pathway (anti-NF-КB, DNA intercalator), G = regulates an enzyme (kinase inhibitors, HDAC inhibitors), I = endogenous compound (melatonin), J = nanoparticle (gold). L = linker for conjugation (valine-citrulline, hydrazine)
| DESIGNING D RUG CONJUGATES

| Drug targets
T A B L E 1 Antibody-drug conjugates for breast cancer Antibody-cytotoxic drug conjugates (ADCs) are the most widely investigated drug conjugates to treat breast cancer. 89 In general, a cytotoxic drug is attached to a monoclonal antibody that is specific for the target receptor ( Figure 2A ). The antibody binds to the receptor of the cancer cell where the cytotoxic drug is intended to exert its actions. Therefore, the cancer cells should ideally densely express the receptor for antibody binding. 
| Linker design
The following questions need to be addressed when designing chemical linkers: Should it be stable in the circulation? Should it release the 2 active drugs at the target site? Should it be stable at the target site? Should it influence drug activity? Stable linkers can be simple (CH 2 ) n -chains (eg, tamoxifen-melatonin drug conjugate or more hydrophilic amides (eg, valine-citrulline linker), and ether-containing spacers (eg, maleimidomethyl cyclohexane-1-carboxylate linker); the design depends on the drugs themselves and sites of attachment;
and on the desired action on the tumor. 24, 74, 116 Furthermore, if the efficacy of the drug conjugate is dependent upon linker stability, then noncleavable linkers may be superior because they can only be degraded once they are internalized by lysosomes within cells. 74 However, it is also possible that the conjugate will exert its action by maintaining the integrity of the linker until it reaches its target site(s) where it will then be broken down chemically or enzymatically depending on the structure of the linker; this type of linker is referred to as a cleavable linker. 74 One drawback to the type of drug conjugate is that the local release of drugs at their target site(s) may also impact neighboring "nontarget" sites, which may cause toxicity depending upon the cellular milieu. 47 Drugs conjugated with a chemically cleavable linker are released under specific biochemical environments. A hydrazone linker is usually stable in standard blood pH conditions (pH 7.4) and hydrolyzed under acidic conditions, such as in lysosomes or in the more acidic tumor microenvironment. 30 For example, adriamycin conjugated to PEO-b-PAsp copolymers with a hydrazone linker exhibited release of the active drug at pH levels below 5. 44 However, one drawback to this type of linker may be its instability in acidic buffers and excipients as observed for hydrazone linkers. 52 In a recent study, a drugantibody conjugate using this type of linker [ie, gemtuzumab ozogamicin (Mylotarg ® )] was withdrawn due to its narrow therapeutic index, poor plasma stability, and lack of benefit over conventional chemotherapy. 30, 74, 88 Even though this was with a drug-antibody conjugate, these findings need to be taken into consideration when designing a drug-drug conjugate.
Chemical linkers containing disulfide bonds are also chemically cleavable. For example, disulfide bonds may be reduced in vivo by glutathione. As glutathione levels are relatively low in plasma (2-20 μmol/L) compared to the cytoplasm (0.5-10 mmol/L) 75, 115, 118 disulfide bond-containing linkers remain relatively stable in blood.
This property improves the pharmacokinetic profiles of the conjugates compared to their unconjugated antibody component. For 20, 21 Radiation emitted from a radionuclide can be used to kill cells. Radioactive compounds can also attack noncancerous cells; therefore, targeted delivery of the radionuclide with the help of a monoclonal antibody is desirable. The radionuclide can be linked to a monoclonal antibody by a linker, or the antibody could be labeled with radioisotope by a chelation method ( Figure 2B ).
example, the disulfide linker containing a doxorubicin-gold drug conjugate exhibited greater intracellular uptake than free doxorubicin in multidrug-resistant cancer cells. 41 One point to consider when creating drug conjugates with a disulfide linker is its stability during the sterilization process. Heat generated during the sterilization process can break down disulfide bonds. 68 This obstacle could be overcome through filter sterilization. 31 Linkers may be designed to be degraded by enzymes within the breast cancer cell to control drug delivery at the target site; this may avoid premature release into the systemic circulation due to factors such as low pH. 30 For example, lysosomal enzymes located in breast cancer cells can be leveraged to design conjugates that will only release the drug intracellularly. A commonly used peptide linker, valine-citrulline, is cleaved by cathepsin B and exhibits superior stability compared to the hydrazone linker. 25 For example, a drug-antibody conjugate (ie, a Lewis Y-specific antibody conjugated to monomethyl auristatin E) connected by a valine-citrulline linker showed superior stability in buffer and plasma, suggesting that the conjugate will release the drug only in the presence of cathepsin. 25 In another study, it was shown that the valine-citrulline linker exhibits greater stability compared to the Phe-Lys peptide linker in the presence of cathepsin B alone, as doxorubicin release from the conjugate was 30-fold faster for the Phe-Lys linker than the valinecitrulline linker. 29 Glucuronide-based linkers can also be used as nonpeptide linkers that release drugs within the interior of the cell through the action of lysosomal β-glucuronidases. inhibit breast cancer cell viability compared to these same drugs connected using a dipeptide linker. 11 Even though these examples were based on drug-antibody conjugates, these approaches may also be useful in designing drug-drug conjugates. The uptake of nanoparticles by a tissue depends on the hydrophobicity of that nanoparticle. For example, nanoparticles deposited in certain organs such as the liver, spleen, and reticuloendothelial system correlate positively with the increasing hydrophobicity of the polymer. 37 Although several nanoparticle-based drug delivery systems have been developed, only albumin-bound paclitaxel nanoparticle (Abraxane ® ) was approved by FDA for metastatic breast cancer and nonsmall cell lung carcinoma. 69 Nanotechnology can also be effectively used in breast cancer treatment. Nanoparticle conjugates may show increased potency by penetrating the cells by endocytosis instead of the diffusion method used for a single drug. 28 This could be a mechanism to avoid efflux by drug transporters such as P-glycoprotein. 14 In a phase III clinical trial, paclitaxel nanoparticles bonded with albumin showed superior efficacy and safety compared to paclitaxel dissolved in castor oil. 39 Furthermore, doxorubicin linked with poly(L-glutamic acid) by a pH-sensitive cleavable linker showed enhanced efficacy in MDA-MB-231 and 4T1 metastatic breast cancer mouse model. The triple drug conjugate platinum-acridine-endoxifen exhibited higher cytotoxicity compared to a tamoxifen/cisplatin combination therapy, which warrants further investigation. 23 Another triple conjugate, 4-hydroxytamoxifen-doxorubicin-formaldehyde showed increased drug uptake in estrogen receptor-positive breast cancer cell lines compared to untargeted doxorubicin−formaldehyde conjugates. 10 These studies further support the versatility and therapeutic efficacy of drug conjugates, which can be expanded from a dual-drug approach to a triple-drug conjugate approach. any effect. 98 The activity of the bivalent conjugate depends on the length of the spacer with a maximal estrogen receptor binding achieved for the (CH 2 OCH 2 )n-linked endoxifen-endoxifen bivalent ligands with an n of 3 or 7 98 ; Table 4 ).
An estradiol-cisplatin hybrid conjugate showed antiproliferative activity in the low micromolar range, which was more potent than cisplatin alone in estrogen-dependent and estrogen-independent breast cancer cell lines MCF-7 and MDA-MB-231, respectively. 59 and lapitanib (EGFR inhibitor) and panabinostat. 70 The concept of drug conjugates can also be used in the development of targeted drug delivery systems. Targeted drug delivery systems are generally stable in the systemic circulation, and they might be designed to release the cytotoxic drugs only after internalization into cancer cells. 49 Some drug conjugates were specifically designed to deliver the cytotoxic drug at the target site using a pharmacologically inactive drug. Examples of tamoxifen drug conjugates targeted for specific drug delivery are described in Table 3 .
| CONCLUSION
Hundreds of receptors and signaling pathways are dysregulated in breast cancer, a highly heterogeneous disease that exploits multiple targets, such as receptors from different classes and myriad signal transduction cascades. 42 Because of these factors, breast cancer drugs Thus, drug conjugates are emerging as a novel and effective treatment approach for breast cancer.
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